BIOL Biolase Inc

Price (delayed)

$0.6655

Market cap

$100.62M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.27

Enterprise value

$78.34M

BIOLASE is a medical device company that develops, manufactures, markets, and sells laser systems in dentistry and medicine. BIOLASE's products advance the practice of dentistry and medicine for patients and ...

Highlights
The company's EPS has surged by 60% YoY and by 31% QoQ
BIOL's gross profit is up by 41% since the previous quarter and by 10% year-on-year
Biolase's gross margin has increased by 14% from the previous quarter but it has decreased by 10% YoY
Biolase's quick ratio has decreased by 18% from the previous quarter

Key stats

What are the main financial stats of BIOL
Market
Shares outstanding
151.19M
Market cap
$100.62M
Enterprise value
$78.34M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.01
Price to sales (P/S)
3.1
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.42
Earnings
Revenue
$32.31M
EBIT
-$11.36M
EBITDA
-$11.17M
Free cash flow
-$13.79M
Per share
EPS
-$0.27
Free cash flow per share
-$0.09
Book value per share
$0.22
Revenue per share
$0.21
TBVPS
$0.39
Balance sheet
Total assets
$61.25M
Total liabilities
$27.99M
Debt
$15.01M
Equity
$33.26M
Working capital
$42.62M
Liquidity
Debt to equity
0.45
Current ratio
4.35
Quick ratio
3.23
Net debt/EBITDA
1.99
Margins
EBITDA margin
-34.6%
Gross margin
33%
Net margin
-42.5%
Operating margin
-57.4%
Efficiency
Return on assets
-26.4%
Return on equity
-60.6%
Return on invested capital
-48.9%
Return on capital employed
-23.4%
Return on sales
-35.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

BIOL stock price

How has the Biolase stock price performed over time
Intraday
-2.88%
1 week
-3.55%
1 month
-9.76%
1 year
129.48%
YTD
58.45%
QTD
-4.67%

Financial performance

How have Biolase's revenue and profit performed over time
Revenue
$32.31M
Gross profit
$10.66M
Operating income
-$18.55M
Net income
-$13.73M
Gross margin
33%
Net margin
-42.5%
BIOL's net margin is up by 43% year-on-year and by 37% since the previous quarter
BIOL's gross profit is up by 41% since the previous quarter and by 10% year-on-year
BIOL's net income is up by 31% year-on-year and by 23% since the previous quarter
Biolase's revenue has increased by 24% from the previous quarter and by 22% YoY

Growth

What is Biolase's growth rate over time

Valuation

What is Biolase stock price valuation
P/E
N/A
P/B
3.01
P/S
3.1
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.42
The company's EPS has surged by 60% YoY and by 31% QoQ
BIOL's price to book (P/B) is 50% less than its 5-year quarterly average of 6.2 and 3.1% less than its last 4 quarters average of 3.2
The stock's price to sales (P/S) is 167% more than its 5-year quarterly average of 1.2 and 33% more than its last 4 quarters average of 2.4
Biolase's revenue has increased by 24% from the previous quarter and by 22% YoY

Efficiency

How efficient is Biolase business performance
The return on assets has surged by 62% year-on-year and by 35% since the previous quarter
Biolase's ROIC has soared by 60% YoY and by 32% from the previous quarter
BIOL's ROE is up by 50% QoQ
The company's return on sales rose by 47% YoY and by 39% QoQ

Dividends

What is BIOL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BIOL.

Financial health

How did Biolase financials performed over time
The company's total assets is 119% higher than its total liabilities
The company's total assets has surged by 121% YoY but it fell by 3.5% QoQ
Biolase's quick ratio has decreased by 18% from the previous quarter
BIOL's debt is 55% smaller than its equity
The debt to equity has plunged by 96% YoY and by 17% from the previous quarter
BIOL's debt is down by 17% since the previous quarter and by 10% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.